Syndax Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Syndax Pharmaceuticals, Inc. (SNDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-12-31 was -$4.00K, a 144.44% decline year-over-year.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was $6.00K.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was $9.00K.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $6.80M, a 5.56% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $7.20M, a 24.21% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $9.50M, a 44.12% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $17.00M, a 68.32% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.80M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $7.20M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $9.50M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $17.00M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $10.10M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $7.10M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.00K derived: sum of 2 quarters · filed 2022-03-01 | $9.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | $6.00K 10-Q · filed 2019-11-07 | $13.00K 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $7.00K 10-Q · filed 2019-08-07 | |||
| 2018-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $9.00K derived: sum of 2 quarters · filed 2021-03-12 | $100.00K 10-K · filed 2021-03-12 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $91.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $91.00K 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $200.00K 10-K · filed 2020-03-05 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $200.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $200.00K 10-Q · filed 2017-08-10 | ||
| 2017-03-31 | $200.00K 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $3.80M 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $200.00K 10-K · filed 2018-03-08 | |||
| 2013-09-30 | $3.70M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |